Immediate applications for RWE Generation under EHDS
- Long-term follow-up of advanced therapies: Enables systematic, cross-border tracking of patients receiving treatments such as CAR T, supporting better understanding of durability, long-term outcomes, and delayed safety risks.
- Enhanced safety surveillance: Larger, pooled datasets improve detection of rare and delayed adverse events and allow more robust assessment of safety and effectiveness across diverse patient populations and real-world settings.
- Expanded research in hard-to-study populations: Facilitates more feasible and statistically robust pregnancy exposure and rare disease studies through access to aggregated populations and longitudinally linked data across jurisdictions.
The establishment of the European Health Data Space (EHDS), formally adopted by the European Union in March 2025, represents a significant transformation in the governance and use of health data across Member States. EHDS introduces a harmonized legal, technical, and operational framework to enable both the primary use of data for healthcare delivery (MyHealth@EU) and its secondary use for research, innovation, and policymaking (HealthData@EU). By strengthening citizen control over personal health information while enabling secure cross-border interoperability, EHDS addresses the longstanding fragmentation of European health data ecosystems.
A central feature of EHDS is the implementation of a permit-based access model for secondary data use. Researchers and organizations, including contract research organizations (CROs), must obtain approval through national Health Data Access Bodies (HDABs), which ensure compliance with requirements related to data protection, ethical governance, and purpose limitation. Access is granted within secure processing environments, where data remain in controlled settings and cannot be exported. This model enhances privacy and security but also introduces constraints on traditional data handling and analysis workflows.
Complementary initiatives such as xShare further reinforce this framework by enabling citizen-mediated sharing of interoperable electronic health record data. By embedding consent mechanisms into standardized data structures, xShare promotes scalable and secure cross-border data access. Together, these initiatives establish the foundations of a unified European infrastructure capable of supporting large-scale real-world evidence (RWE) generation.
Implications for CROs: From Data custodians to data users
The implementation of EHDS fundamentally reshapes the role of CROs in RWE generation. Historically, CROs operated in a fragmented regulatory landscape, acting as intermediaries that aggregated and managed datasets from multiple sources. They maintained direct control over data storage, processing, and integration, often navigating diverse national requirements and heterogeneous data standards. EHDS replaces this model with a regulated framework in which CROs act as authorized data users or processors within tightly controlled environments.
This transition reduces direct control over raw data while increasing accountability. CROs must now operate within secure platforms governed by HDABs, ensuring compliance with approved study protocols and regulatory standards. Auditability and transparency, already fundamental expectations, are further reinforced, with all data access and analytical activities subject to oversight by HDABs. Consequently, methodological rigor, high-quality documentation, and reproducibility are further emphasized as critical success factors, reinforcing the convergence of RWE practices with the standards applied in interventional clinical research.
EHDS also accelerates the standardization of real-world data through common data models and interoperability frameworks. This harmonization addresses persistent challenges related to data heterogeneity and enables more consistent and comparable analyses across jurisdictions. However, it requires CROs to invest in advanced data engineering capabilities, including scalable data ingestion and integration capacity, alignment of clinical definitions and coding standards, and reproducible analytical workflows.
Operational transformation and methodological rigor under EHDS
EHDS introduces a more formalized operational model for RWE studies, requiring analyses within secure processing environments, while reinforcing compliance, traceability, and audit readiness with are longstanding pillars of clinical research practice. CROs must implement robust quality management systems and collaborate closely with HDABs and data providers to ensure adherence to regulatory requirements throughout the data lifecycle.
Reproducibility and transparency, already foundational in clinical research, are further reinforced in this evolving framework. Analytical processes are expected to remain fully documented and version-controlled, enabling independent verification of results. Study protocols are increasingly expected to be predefined and, in some cases, publicly registered, reflecting broader adoption of open science principles. These expectations further strengthen the scientific credibility of RWE and support its acceptance in regulatory decision-making.
The adoption of standardized data models also enables more efficient multi-country analyses by reducing the need for extensive data cleaning and transformation. However, CROs must maintain expertise in both technical and contextual domains, as variations in healthcare systems and data practices persist across Member States. Continuous investment in training and infrastructure is therefore essential to ensure sustained compliance and operational efficiency.
Data access, interoperability, and cross-border research enablement
A defining advantage of EHDS is its ability to support cross-border research through harmonized data access and interoperability. By aligning technical standards and governance processes, EHDS reduces barriers that have historically limited multinational studies. The centralized role of HDABs ensures a consistent authorization process, while interoperable datasets facilitate integrated and large-scale analyses.
For CROs, this creates new opportunities to design pan-European studies with greater statistical power and broader population coverage. Access to diverse datasets allows for more robust evaluations of treatment effectiveness, particularly in rare diseases or heterogeneous patient populations. The ability to link data across domains, such as hospital, registry, and prescribing data, supports more comprehensive longitudinal research.
At the same time, these opportunities introduce additional complexity. Differences in data completeness, coding practices, and healthcare delivery systems must still be considered in study design and interpretation. Successfully leveraging EHDS therefore requires both technical capability and a nuanced understanding of regional healthcare contexts.
Strategic opportunities and future outlook for RWE generation
EHDS is expected to strengthen the role of RWE in regulatory and health technology assessment (HTA) decision-making. As authorities increasingly rely on real-world data to support approvals, reimbursement decisions, and post-market surveillance, the demand for high-quality, transparent, and scientifically robust evidence continues to grow. CROs must demonstrate methodological excellence, traceability of data sources, and adherence to rigorous analytical standards to meet these expectations.
While the transition to EHDS introduces operational complexity and increased costs, it also creates strategic opportunities. CROs that align early with EHDS requirements can establish themselves as trusted partners capable of delivering regulator-ready RWE at scale. The ability to operate effectively within this harmonized framework will differentiate organizations in an increasingly competitive landscape.
In conclusion, EHDS represents a transformative milestone in European health data governance. By transitioning from a fragmented system to a standardized and regulated framework, it redefines the role of CROs and elevates the quality and impact of RWE. Organizations that invest in compliance, interoperability, and methodological rigor will be well positioned to contribute to a more integrated, data-driven, and patient-centered healthcare system across Europe.
Jennifer Eriksson, Divisional Principal, Insights, Evidence & Value, Health Economics & Epidemiology, ICON Commercial Solutions; Stéphanie Rio, Senior Director, Project Management, Real World Solutions, ICON Commercialization & Outcomes; and Alexandre Malouvier, Senior Director, Scientific, Affairs & Digital Innovation, Mapi Research Trust, ICON Patient Centered Sciences
